Praziquantel Associated With Alkaloid in the Treatment of Schistosomosis: technological prospection in na innovative perspective

• Autor(a) principal: Gerônimo Neto, Pedro da Silva
• Data de Publicação: 2021
• Outros Autores: Ferreira, João Marcelo Saraiva, Monteiro, Pablo de Matos, Bandeira, Maria Glória Almeida, Nascimento, Jaqueline Silva
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Cadernos de Prospecção (Online)
• Texto Completo: https://periodicos.ufba.br/index.php/nit/article/view/33066
• topic: Praziquantel; Patentes; Artigos Científicos.; Praziquantel; Patent; Scientific Article.

Schistosomiasis is a neglected disease triggered by Schistosoma mansoni. Praziquantel (PZQ) is the drug of choice in the treatment of schistosomiasis, in addition to other neglected diseases caused by helminths, however, the difficulty in adhering to the treatment and the incorrect use of this medication has demonstrated the parasite’s resistance to praziquantel. For the preparation of this article, patents and articles from the main studies related to praziquantel were prospected. The search was carried out on the basis of the National Institute of Industrial Property (INPI) of Brazil, the European Patent Office (Espacenet), the Derwent Innovations Index, the World Intellectual Property Organization (WIPO) and also on articles indexed in Scielo and Scopus. The same keywords were used for searches in the patent bases and in the scientific article bases for the period from 2008 to 2018. Brazil presented the largest number of articles published in the SCIELO database for the period under study, however this is not reflected in patent applications, in which countries such as the United States and China are the largest holders of patent applications.